2,264 Shares in Gilead Sciences, Inc. $GILD Bought by Groupe la Francaise

Key Points

• Groupe la Francaise has acquired a new position in Gilead Sciences, purchasing 2,264 shares valued at approximately $252,000.
• Gilead Sciences recently reported earnings of $2.01 per share, exceeding expectations, along with a quarterly revenue of $7.08 billion.
• Multiple analysts have upgraded their ratings for Gilead Sciences, with the consensus target price now set at $115.39.

Groupe la Francaise purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,264 shares of the biopharmaceutical company's stock, valued at approximately $252,000.

Several other institutional investors and hedge funds have also made changes to their positions in GILD. Brighton Jones LLC raised its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Integrated Wealth Concepts LLC raised its position in shares of Gilead Sciences by 4.7% during the 4th quarter. Integrated Wealth Concepts LLC now owns 26,687 shares of the biopharmaceutical company's stock valued at $2,465,000 after acquiring an additional 1,194 shares in the last quarter. Nebula Research & Development LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $288,000. Two Sigma Securities LLC raised its position in shares of Gilead Sciences by 164.4% during the 4th quarter. Two Sigma Securities LLC now owns 2,253 shares of the biopharmaceutical company's stock valued at $208,000 after acquiring an additional 5,753 shares in the last quarter. Finally, Capital Analysts LLC raised its position in shares of Gilead Sciences by 8.5% during the 4th quarter. Capital Analysts LLC now owns 5,444 shares of the biopharmaceutical company's stock valued at $503,000 after acquiring an additional 426 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on GILD. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Royal Bank Of Canada upped their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, UBS Group increased their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $114.77 on Monday. Gilead Sciences, Inc. has a 1-year low of $75.91 and a 1-year high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The business's fifty day moving average price is $112.51 and its two-hundred day moving average price is $109.16. The firm has a market capitalization of $142.41 billion, a PE ratio of 22.86, a P/E/G ratio of 0.70 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period last year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the transaction, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,339,230 over the last three months. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.